Canaccord Genuity Maintains Buy on Boston Scientific, Lowers Price Target to $48
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice TargetHot
Canaccord Genuity analyst William Plovanic maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $66 to $48.
Canaccord Genuity analyst William Plovanic maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $66 to $48.